European Medicines Agency approves cabazitaxel


According to a media release from Sanofi-Aventis and a report on the Reuters web site today, the European Medicines Agency (EMEA) has approved cabazitaxel (Jevtana) as a form of second-line chemotherapy for treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have received prior treatment with a docetaxel-based chemotherapy regimen.

Cabazitaxel was approved in the USA for the same indication in June 2010. Data from the Phase III TROPIC study that formed the basis for the approval of cabazitaxel in the US and Europe has been discussed previously on this site.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 1,115 other followers